## HRL: Hormel Foods Corporation - XLP: Consumer Defensive

### Executive Summary

No thesis match: MRS_10 -0.2% below STRENGTH zone (3.0-6.0%); PEG 3.39 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-2.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($22.66)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_10 falling below -5% or breaking key support

### News

- **Articles:** 10
- **Sentiment:** Neutral (Bullish: 2, Bearish: 0)

**1. Hormel Foods reports lower earnings despite higher sales as profit drops hit US$56.1M loss**
- Source: Food Business Africa Magazine | 20251208T121508 | Neutral | Relevance: 99%
-  Hormel Foods experienced a significant decline in profitability in fiscal 2025, reporting a net loss of US$56.1 million for the fourth quarter despite slightly higher revenue. The company attributed the profit drop to persistent cost inflation and discrete financial impacts, leading to a full-year net earnings decrease. Looking ahead to 2026, Hormel plans to refine its product mix and improve operational efficiency to reshape its earnings trajectory.

**2. ROSEN, LEADING TRIAL ATTORNEYS, Encourages Hormel Foods Corporation Investors to Inquire About Securities Class Action Investigation â€“ HRL**
- Source: GlobeNewswire | 20251209T220841 | Neutral | Relevance: 99%
- The Rosen Law Firm has announced an investigation into potential securities claims against Hormel Foods Corporation (NYSE: HRL) after allegations of materially misleading business information were issued to the public. This follows a Wall Street Journal article stating Hormel cut its forecast due to price pressures, bird flu, and a fire, accompanied by a 9.1% stock drop. Investors who purchased Hormel securities are encouraged to contact Rosen Law Firm to inquire about joining a potential class action lawsuit for compensation.

**3. Hormel Foods seeks to capitalize on protein**
- Source: Baking Business | 20251208T130829 | Neutral | Relevance: 99%
- Hormel Foods is focusing on its legacy as a protein provider, rolling out new products like sandwich-ready bacon and expanding its chicken offerings with brands like Applegate Farms, despite facing significant challenges from surging commodity prices in fiscal 2025. The company's net income for the year decreased, impacted by inflation in raw materials and impairment charges, yet they project growth in net sales and adjusted operating income for fiscal 2026. Hormel is also reshaping its portfolio, recently moving its Justin's business into a strategic partnership and exiting certain private label product lines.

**4. Rosen Law Firm Encourages Hormel Foods Corporation Investors to Inquire About Securities Class Action Investigation - HRL**
- Source: KWKT - FOX 44 | 20251209T012622 | Neutral | Relevance: 98%
-  Rosen Law Firm is investigating potential securities claims against Hormel Foods Corporation (HRL) following allegations that the company issued misleading business information. This probe comes after a Wall Street Journal article reported Hormel's reduced earnings forecast due to price pressures, bird flu, and a fire, which also led to a CFO change and a 9.1% stock drop. Investors who purchased Hormel securities are encouraged to contact the firm regarding their eligibility to join a prospective class action.

**5. Night Squared LP Purchases Shares of 236,242 Hormel Foods Corporation $HRL**
- Source: MarketBeat | 20251210T125348 | Somewhat-Bullish | Relevance: 98%
-  Night Squared LP acquired a new position in Hormel Foods Corporation, purchasing 236,242 shares valued at approximately $7.146 million, making it their 8th biggest holding. Several other hedge funds have also adjusted their positions in Hormel Foods, and analysts have set various price targets and ratings for the stock. Hormel Foods recently delivered quarterly earnings topping estimates and increased its quarterly dividend.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 3, Lowers: 2)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $30 | $31 | -3% |
| 2025-12-05 | Piper Sandler | $26 | $25 | +4% |
| 2025-12-05 | JP Morgan | $28 | $27 | +4% |
| 2025-12-05 | B of A Securiti | $26 | $25 | +4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | main | Overweight |
| 2025-12-05 | Piper Sandler | main | Neutral |
| 2025-12-05 | JP Morgan | main | Overweight |
| 2025-12-05 | B of A Securiti | main | Neutral |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 4 ($0.26M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 24.9% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 10 / 0 |

**Top Holders:**
- Vanguard Group Inc: 6.8% (+2.0%)
- State Street Corpora: 5.1% (+1.0%)
- Blackrock Inc.: 4.6% (+2.2%)
- Invesco Ltd.: 2.1% (+66.5%)
- Geode Capital Manage: 1.5% (+1.7%)

### Key Risks

1. Valuation risk: PEG 3.4x with declining EPS estimates leaves no margin for error.
2. Long-term trend broken: trading 13.8% below SMA200.
3. Market regime shift could impact momentum names disproportionately.

### Catalysts

- Analyst target momentum: 3 raises (avg +4%) could attract flows.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 3.39 signals overvaluation risk, limited margin of safety. Forward P/E 15.2x stretched relative to 7% growth. Balance sheet: strong liquidity (2.5x), low leverage (D/E 0.18). Institutional flow bullish (10 buying vs 0 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $13.1B |
| Beta | 0.33 |
| 52W Range | $21.03 - $33.80 |
| Short Interest | 5.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 3.39 |
| Forward P/E | 15.2 |
| Current P/E | 16.2 |
| YoY Growth | 6.9% |
| EPS Direction | FALLING |

### Technicals

MRS_10 deteriorating from 2.6% to -0.2% (-2.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 3.2pp (needs >3.0% for momentum thesis). Below SMA200 (0.86x), long-term trend not supportive. RSI neutral at 58.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_10 | -0.16% (CS: 48) | Neutral |
| RSI_14 | 57.9 | Neutral |
| MACD Histogram | 0.15 | Bullish |
| vs SMA20 | 1.030x | Above |
| vs SMA50 | 1.025x | Above |
| vs SMA200 | 0.862x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $23.74
- **Stop Loss:** $22.66 (4.5% risk)
- **Target:** $24.82 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 462
- **Position Value:** $10,967.88
- **Portfolio %:** 10.97%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

*NORMAL regime with signs of improving risk appetite. Multiple major banks lowering prime rates suggest a dovish tilt in financial conditions ahead of the FOMC, while volatility remains subdued and breadth is moderate. Key drivers are easing lending rates, stable macro data, and improving sentiment, but selectivity is needed due to sector divergences.*

### Earnings

**Next:** 2026-02-26 (Est: $0.32)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q4 | $0.30 | $0.32 | +6.0% |
| 2025Q3 | $0.41 | $0.35 | -14.5% |
| 2025Q2 | $0.34 | $0.35 | +3.3% |
| 2025Q1 | $0.37 | $0.35 | -6.6% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_10*